lapatinib has been researched along with nelfinavir in 7 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (nelfinavir) | Trials (nelfinavir) | Recent Studies (post-2010) (nelfinavir) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 1,240 | 230 | 240 |
| Protein | Taxonomy | lapatinib (IC50) | nelfinavir (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 7.971 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 8.852 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 3.3938 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.275 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 2.3 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 8.852 | |
| Protease | Human immunodeficiency virus 1 | 0.53 | |
| Protease | Human immunodeficiency virus 1 | 0.0054 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Anderson, KS; Cabeza de Vaca, I; Deshmukh, M; Ghahremanpour, MM; Ippolito, JA; Jorgensen, WL; Liosi, ME; Tirado-Rives, J; Zhang, CH | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Baerman, KM; Calvo, BF; Cox, AD; Kimple, RJ; Sartor, CI; Shields, JM; Tepper, JE; Vaseva, AV | 1 |
3 review(s) available for lapatinib and nelfinavir
| Article | Year |
|---|---|
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
4 other study(ies) available for lapatinib and nelfinavir
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
Topics: | 2020 |
Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Female; Genes, ras; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mutation; Nelfinavir; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |